Levin Capital Strategies L.P. Sells 634,723 Shares of Fluidigm Co. (FLDM)

Levin Capital Strategies L.P. lowered its position in shares of Fluidigm Co. (NASDAQ:FLDM) by 6.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,567,068 shares of the medical research company’s stock after selling 634,723 shares during the period. Fluidigm accounts for approximately 1.8% of Levin Capital Strategies L.P.’s investment portfolio, making the stock its 21st biggest holding. Levin Capital Strategies L.P. owned approximately 24.33% of Fluidigm worth $82,468,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Chicago Equity Partners LLC bought a new position in shares of Fluidigm during the fourth quarter valued at approximately $313,000. Algert Global LLC purchased a new stake in shares of Fluidigm during the fourth quarter valued at approximately $483,000. Rhumbline Advisers grew its holdings in shares of Fluidigm by 42.9% during the fourth quarter. Rhumbline Advisers now owns 34,489 shares of the medical research company’s stock valued at $297,000 after buying an additional 10,358 shares during the last quarter. Quantamental Technologies LLC purchased a new stake in shares of Fluidigm during the fourth quarter valued at approximately $61,000. Finally, Vanguard Group Inc grew its holdings in shares of Fluidigm by 9.5% during the third quarter. Vanguard Group Inc now owns 1,410,526 shares of the medical research company’s stock valued at $10,565,000 after buying an additional 121,815 shares during the last quarter. Institutional investors own 96.95% of the company’s stock.

In related news, insider Levin Capital Strategies, L.P. purchased 35,033 shares of Fluidigm stock in a transaction on Monday, December 10th. The shares were bought at an average cost of $7.72 per share, for a total transaction of $270,454.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders acquired 1,083,700 shares of company stock worth $7,387,908. 2.20% of the stock is currently owned by insiders.

A number of equities research analysts have recently commented on FLDM shares. Zacks Investment Research cut shares of Fluidigm from a “hold” rating to a “sell” rating in a report on Wednesday, January 16th. ValuEngine upgraded shares of Fluidigm from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. BidaskClub upgraded shares of Fluidigm from a “hold” rating to a “buy” rating in a report on Thursday, December 27th. Janney Montgomery Scott upgraded shares of Fluidigm from a “neutral” rating to a “buy” rating in a report on Thursday, January 3rd. Finally, Piper Jaffray Companies upgraded shares of Fluidigm from a “neutral” rating to an “overweight” rating in a report on Friday, November 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $9.25.

Shares of NASDAQ FLDM opened at $9.58 on Monday. The company has a debt-to-equity ratio of 7.56, a quick ratio of 1.45 and a current ratio of 1.85. The firm has a market capitalization of $367.67 million, a price-to-earnings ratio of -11.98 and a beta of 2.29. Fluidigm Co. has a 52-week low of $4.65 and a 52-week high of $9.76.

Fluidigm (NASDAQ:FLDM) last announced its quarterly earnings results on Thursday, February 7th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. The company had revenue of $32.33 million for the quarter, compared to the consensus estimate of $30.55 million. Fluidigm had a negative net margin of 52.24% and a negative return on equity of 90.07%. On average, equities analysts forecast that Fluidigm Co. will post -0.81 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.themarketsdaily.com/2019/02/11/levin-capital-strategies-l-p-sells-634723-shares-of-fluidigm-co-fldm.html.

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Featured Article: What are the components of an earnings report?

Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Co. (NASDAQ:FLDM).

Institutional Ownership by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply